BILLERICA, Mass. --(BUSINESS WIRE)--Aug. 6, 2024-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue and Chief Financial Officer Vandana Sriram will speak in a fireside

BILLERICA, Mass. --(BUSINESS WIRE)--Jul. 31, 2024-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Thursday, August 8, 2024 at 4:30 p.m. E.T.

Quanterix improves on its best-in-class p-Tau 217 standalone test with new multi-marker approach reducing the number of patients receiving uncertain results BILLERICA, Mass. --(BUSINESS WIRE)--Jul. 29, 2024-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through

BILLERICA, Mass. --(BUSINESS WIRE)--Jun. 17, 2024-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer, Masoud Toloue , and Chief Financial Officer, Vandana Sriram , will attend the

BILLERICA, Mass. --(BUSINESS WIRE)--Jun. 5, 2024-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will speak at the Goldman Sachs 45th Annual Global Healthcare

BILLERICA, Mass. --(BUSINESS WIRE)--May 22, 2024-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will speak in a fireside chat at the 2024 Leerink Partners

BILLERICA, Mass. --(BUSINESS WIRE)--May 7, 2024-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the first quarter ended March 31, 2024 . “Building on the foundation our team developed

BILLERICA, Mass. --(BUSINESS WIRE)--Apr. 29, 2024-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Wednesday, May 8, 2024 at 8:30 a.m. E.T.

BILLERICA, Mass. --(BUSINESS WIRE)--Mar. 21, 2024-- Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, today announced a specific partnership path for laboratories interested in offering Tau based research and diagnostic

BILLERICA, Mass. --(BUSINESS WIRE)--Mar. 4, 2024-- Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, announced today that its Simoa ® phospho-Tau 217 (p-Tau 217) blood test has been granted Breakthrough Device designation